PetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical Device
MWN-AI** Summary
PetVivo Holdings, Inc. has announced a significant regulatory milestone as Health Canada has formally acknowledged its product, Spryng® with OsteoCushion® Technology, as a veterinary medical device for use in Canada. This recognition is crucial for PetVivo's global commercialization strategy, affirming the product's compliance with Health Canada's standards for veterinary devices aimed at enhancing joint health and managing lameness in animals.
Spryng is an intra-articular injectable device administered by veterinarians, designed to offer innovative solutions for joint-related issues in companion animals and equine athletes. John Lai, CEO of PetVivo Holdings, expressed optimism regarding this endorsement from Health Canada, indicating that it highlights the company's commitment to providing effective solutions that improve animal health and mobility. The company plans to further advance Spryng's availability in Canada, expecting potential market entry in the second quarter of 2026.
However, immediate availability of Spryng in Canada will depend on several preparations, including the establishment of distribution infrastructure and the creation of Canada-specific packaging and labeling. Although currently available in the United States and select international markets, the acknowledgment from Health Canada supports PetVivo's vision of bringing transformative veterinary solutions to a broader audience.
PetVivo is not only focusing on Spryng but is also committed to leveraging its robust pipeline of innovative medical devices for companion animals. The company holds twelve patents and six trade secrets, ensuring protection over its processes and products. Its lead products, including Spryng and PrecisePRP®, are part of a strategy that aims to expedite the introduction of veterinary medical devices compared to traditional pharmaceuticals, thereby enhancing animal care availability in the market.
MWN-AI** Analysis
PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) recently announced a significant milestone with Health Canada's acknowledgment of Spryng® with OsteoCushion® Technology as a veterinary medical device. This endorsement enhances the company's position in the market and reflects its commitment to expanding access to innovative healthcare solutions for companion animals and equestrian athletes.
This regulatory approval is a pivotal step in PetVivo's commercialization strategy as it enters the Canadian market, potentially projected for the second quarter of 2026. While immediate availability may be hindered by distribution infrastructure and regulatory preparations, the long-term implications are promising. The acknowledgment positions Spryng as a credible alternative for veterinarians in Canada, which could lead to increased sales and market penetration in the North American veterinary industry.
PetVivo's strategy of leveraging human medical technologies in the veterinary space is noteworthy and could expedite revenue generation compared to traditional pharmaceuticals. With a robust pipeline protected by a portfolio of patents and trade secrets, the company is well-equipped to offer additional innovative medical devices and therapeutics, further solidifying its foothold in the veterinary market.
However, investors should be cautious of the operational challenges and execution risks associated with entering new markets. The development of Canadian-specific distribution channels and packaging could delay revenue realization despite the regulatory approval. Given these factors, while the immediate market response may be optimistic, a thorough assessment of the company's operational capabilities is warranted.
In summary, PetVivo Holdings shows significant promise with the acknowledgment of Spryng® in Canada, but investors should remain aware of the potential hurdles in its path to commercialization. This presents an intriguing opportunity for long-term growth as the company navigates these challenges.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MINNEAPOLIS, MN, Jan. 21, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., in cooperation with its parent PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and affiliate PetVivo AI, Inc., an emerging biomedical device company focused on innovative medical technologies for companion animals and equine athletes, today announced that Health Canada has formally acknowledged Spryng® with OsteoCushion® Technology as a veterinary medical device for use in Canada.
Spryng is a veterinarian-administered, intra-articular injectable device developed to support joint health and aid in the management of lameness and other joint-related afflictions in animals. This regulatory acknowledgement by Health Canada represents a key milestone in the Company’s global commercialization strategy and underscores the product’s recognition by a major international regulatory authority.
“Receiving acknowledgment from Health Canada that Spryng meets the criteria for a veterinary medical device is an important endorsement of our scientific and regulatory strategy,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “This acknowledgment reflects our continued commitment to expanding access to innovative, safe, and effective solutions that improve the health and mobility of companion animals and athletic equines. We look forward to advancing Spryng’s availability in Canada as part of our broader global growth plan.”
While Health Canada’s acknowledgement represents an important regulatory milestone, Spryng is not expected to be immediately available in Canada due to ongoing distribution infrastructure development, Canadian-specific packaging and labeling preparations, and other operational requirements. Subject to the completion of these items, the Company currently anticipates a potential commercial availability in Canada in the second calendar quarter of 2026.
Spryng with OsteoCushion Technology has garnered interest from veterinarians and animal health partners worldwide, and this latest regulatory milestone further supports PetVivo’s efforts to bring transformative joint support solutions to the global veterinary market.
Spryng is commercially available in the United States and through select distribution partners internationally.
For more information about Spryng and PrecisePRP, please contact info1@petvivo.com or visit petvivo.com, petvivoanimalhealth.com and sprynghealth.com.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ**
How does the acknowledgment of Spryng® with OsteoCushion® Technology by Health Canada impact the market potential for PetVivo Holdings Inc. Warrant PETVW in Canada?
What specific operational requirements must PetVivo Holdings Inc. complete before Spryng® becomes commercially available in Canada, and how does this affect investor outlook for PETVW?
Considering PetVivo Holdings Inc. Warrant PETVW, what are the anticipated revenue timelines for Spryng® and its potential impact on the company's growth strategy?
How will the international interest from veterinarians in Spryng® influence the valuation of PetVivo Holdings Inc. Warrant PETVW in upcoming quarters?
**MWN-AI FAQ is based on asking OpenAI questions about PetVivo Holdings Inc. Warrant (OTC: PETVW).
NASDAQ: PETVW
PETVW Trading
0.07% G/L:
$0.0344 Last:
5,000 Volume:
$0.034375 Open:
